Chartsonlygoup's future update (it'll live): tomwong.xyz/stock-status/

  Alexion Pharmaceuticals Inc ( ALXN ) |
1995 - 2021 (27 years)

Net Revenue (Sales) is 
$6.2B (1Y +11.9% )

ALXN Income Statement
Line Item (in $M) FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2005 FY 2005 FY 2005 FY 2005 FY 2005 FY 2005 FY 2005 FY 2005 FY 2005 FY 2005 FY 2005 FY 2005 FY 2005 FY 2005 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000 FY 1999 FY 1998 FY 1997
1 Revenue 6069900000.00 4991100000.00 4131200000.00 3551100000.00 3084000000.00 2604047000.00 2233733000.00 1551346000.00 1134114000.00 783431000.00 540957000.00 386800000.00 259099000.00 72041000.00 1558000.00 1064000.00 700000.00 1064000.00 700000.00 1064000.00 700000.00 1064000.00 700000.00 1064000.00 700000.00 1064000.00 700000.00 1064000.00 700000.00 1064000.00 700000.00 4609000.00 877000.00 6536000.00 11805000.00 21441000.00 18800000.00 5000000.00 3800000.00
2 Cost of Revenue 553500000.00 394500000.00 374300000.00 454200000.00 258000000.00 233089000.00 173862000.00 177556000.00 72837000.00 93140000.00 64437000.00 45059000.00 28366000.00 6696000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
3 Gross Profit (Income) 5516400000.00 4596600000.00 3756900000.00 3096900000.00 2826000000.00 2370958000.00 2059871000.00 1373790000.00 1061277000.00 690291000.00 476520000.00 341741000.00 230733000.00 65345000.00 0.00 0.00 700000.00 0.00 700000.00 0.00 700000.00 0.00 700000.00 0.00 700000.00 0.00 700000.00 0.00 700000.00 0.00 700000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
4 R&D 1002900000.00 886000000.00 730400000.00 878400000.00 757000000.00 709472000.00 513782000.00 317093000.00 222732000.00 137421000.00 98394000.00 81915000.00 62581000.00 68961000.00 83225000.00 91388000.00 48200000.00 91388000.00 48200000.00 91388000.00 48200000.00 91388000.00 48200000.00 91388000.00 48200000.00 91388000.00 48200000.00 91388000.00 48200000.00 91388000.00 48200000.00 59840000.00 71042000.00 60005000.00 38871000.00 40187000.00 23700000.00 12300000.00 9100000.00
5 SG&A 1399900000.00 1261100000.00 1111800000.00 1094400000.00 954000000.00 862595000.00 630209000.00 489720000.00 384678000.00 308176000.00 227488000.00 172767000.00 133543000.00 96142000.00 54879000.00 18951000.00 12800000.00 18951000.00 12800000.00 18951000.00 12800000.00 18951000.00 12800000.00 18951000.00 12800000.00 18951000.00 12800000.00 18951000.00 12800000.00 18951000.00 12800000.00 14459000.00 10621000.00 7993000.00 7135000.00 4175000.00 3000000.00 2700000.00 2800000.00
6 Other Expenses -3300000.00 35900000.00 5500000.00 300000.00 0.00 0.00 3401000.00 -1741000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 1931000.00 0.00 1931000.00 0.00 1931000.00 0.00 1931000.00 0.00 1931000.00 0.00 1931000.00 0.00 1931000.00 0.00 1931000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
7 Operating Expenses 2656500000.00 2456700000.00 2162300000.00 2292900000.00 2033000000.00 1688651000.00 1143991000.00 807230000.00 607827000.00 445979000.00 325882000.00 254682000.00 196124000.00 165103000.00 138643000.00 111403000.00 61000000.00 111403000.00 61000000.00 111403000.00 61000000.00 111403000.00 61000000.00 111403000.00 61000000.00 111403000.00 61000000.00 111403000.00 61000000.00 111403000.00 61000000.00 75059000.00 84223000.00 67998000.00 48907000.00 44362000.00 26700000.00 15000000.00 11900000.00
8 Interest Expense 104700000.00 77800000.00 98200000.00 98400000.00 97000000.00 47744000.00 2982000.00 4112000.00 7402000.00 788000.00 704000.00 606000.00 2407000.00 0.00 0.00 0.00 1192000.00 0.00 1192000.00 0.00 1192000.00 0.00 1192000.00 0.00 1192000.00 0.00 1192000.00 0.00 1192000.00 0.00 1192000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
9 D&A 253700000.00 309600000.00 320100000.00 320100000.00 322000000.00 116584000.00 46939000.00 417000.00 417000.00 382000.00 15792000.00 12473000.00 7608000.00 4927000.00 3706000.00 3682000.00 1600000.00 3682000.00 1600000.00 3682000.00 1600000.00 3682000.00 1600000.00 3682000.00 1600000.00 3682000.00 1600000.00 3682000.00 1600000.00 3682000.00 1600000.00 3593000.00 3726000.00 3562000.00 2901000.00 1769000.00 900000.00 600000.00 700000.00
10 EBITDA 3113600000.00 2449500000.00 1914700000.00 1124100000.00 1115000000.00 798891000.00 962819000.00 566977000.00 453867000.00 244694000.00 166430000.00 99532000.00 42217000.00 -94831000.00 -133379000.00 -106657000.00 -58700000.00 -106657000.00 -58700000.00 -106657000.00 -58700000.00 -106657000.00 -58700000.00 -106657000.00 -58700000.00 -106657000.00 -58700000.00 -106657000.00 -58700000.00 -106657000.00 -58700000.00 -66857000.00 -79620000.00 -57900000.00 -34201000.00 -21152000.00 -7000000.00 -9400000.00 -7400000.00
11 Operating Income 2859900000.00 2139900000.00 1594600000.00 804000000.00 793000000.00 682307000.00 915880000.00 566560000.00 453450000.00 244312000.00 150638000.00 87059000.00 34609000.00 -99758000.00 -137085000.00 -110339000.00 -60300000.00 -110339000.00 -60300000.00 -110339000.00 -60300000.00 -110339000.00 -60300000.00 -110339000.00 -60300000.00 -110339000.00 -60300000.00 -110339000.00 -60300000.00 -110339000.00 -60300000.00 -70450000.00 -83346000.00 -61462000.00 -37102000.00 -22921000.00 -7900000.00 -10000000.00 -8100000.00
12 Other Income Expenses (Net) -2186200000.00 116700000.00 -1254200000.00 -157800000.00 -120000000.00 -136421000.00 -40791000.00 -36179000.00 -48482000.00 -15767000.00 -2434000.00 -3139000.00 2528000.00 9212000.00 -580000.00 5885000.00 0.00 5885000.00 0.00 5885000.00 0.00 5885000.00 0.00 5885000.00 0.00 5885000.00 0.00 5885000.00 0.00 5885000.00 0.00 -760000.00 -2560000.00 0.00 -21000000.00 0.00 1500000.00 2100000.00 800000.00
13 Pre-Income Tax 569000000.00 2178800000.00 242200000.00 547800000.00 576000000.00 498142000.00 872107000.00 526269000.00 397566000.00 229668000.00 149011000.00 83314000.00 34730000.00 -93035000.00 -131887000.00 -109515000.00 -58400000.00 -109515000.00 -58400000.00 -109515000.00 -58400000.00 -109515000.00 -58400000.00 -109515000.00 -58400000.00 -109515000.00 -58400000.00 -109515000.00 -58400000.00 -109515000.00 -58400000.00 -74786000.00 -85231000.00 -57242000.00 -47925000.00 0.00 0.00 0.00 0.00
14 Income Tax Expense -34400000.00 -225500000.00 164600000.00 104500000.00 177000000.00 353757000.00 215195000.00 273374000.00 142744000.00 54353000.00 51981000.00 -211852000.00 1581000.00 -745000.00 -373000.00 -765000.00 -500000.00 -765000.00 -500000.00 -765000.00 -500000.00 -765000.00 -500000.00 -765000.00 -500000.00 -765000.00 -500000.00 -765000.00 -500000.00 -765000.00 -500000.00 -691000.00 -764000.00 -700000.00 0.00 0.00 0.00 0.00 0.00
15 Net Income 603400000.00 2404300000.00 77600000.00 443300000.00 399000000.00 144385000.00 656912000.00 252895000.00 254822000.00 175315000.00 97030000.00 295166000.00 33149000.00 -92290000.00 -131514000.00 -108750000.00 -58000000.00 -108750000.00 -58000000.00 -108750000.00 -58000000.00 -108750000.00 -58000000.00 -108750000.00 -58000000.00 -108750000.00 -58000000.00 -108750000.00 -58000000.00 -108750000.00 -58000000.00 -74095000.00 -84467000.00 -56542000.00 -57043000.00 -20227000.00 -6400000.00 -7900000.00 -7300000.00
16 EPS 2.74 10.77 0.35 1.98 1.78 0.68 3.32 1.29 1.34 0.96 0.55 1.73 0.21 -0.64 -1.04 -0.97 -0.48 -0.97 -0.48 -0.97 -0.48 -0.97 -0.48 -0.97 -0.48 -0.97 -0.48 -0.97 -0.48 -0.97 -0.48 -0.86 -1.16 -0.78 -0.82 -0.36 -0.14 -0.22 -0.24
17 EPS Diluted 2.72 10.70 0.35 1.97 1.76 0.67 3.26 1.27 1.28 0.91 0.52 1.63 0.20 -0.64 -1.04 -0.97 -0.48 -0.97 -0.48 -0.97 -0.48 -0.97 -0.48 -0.97 -0.48 -0.97 -0.48 -0.97 -0.48 -0.97 -0.48 -0.86 -1.16 -0.78 -0.82 -0.36 -0.14 -0.22 -0.24
18 Shares Outstanding 219100000 223200000 222700000 223900000 224000000 213431000 198103000 195532000 190461000 183220000 178542000 170652000 155360000 145244000 126804000 111408000 122100000 111408000 122100000 111408000 122100000 111408000 122100000 111408000 122100000 111408000 122100000 111408000 122100000 111408000 122100000 86488000 72836000 72584000 69484000 55656000 45060000 40225356 29803048
19 Shares Outstanding (Diluted) 219100000 224800000 224500000 225400000 227000000 215933000 201623000 199712000 198501000 191806000 186074000 181164000 179934000 145244000 126804000 111408000 122100000 111408000 122100000 111408000 122100000 111408000 122100000 111408000 122100000 111408000 122100000 111408000 122100000 111408000 122100000 86488000 72836000 72584000 69484000 55656000 45060000 40225356 29803048
Net Revenue (Sales) for ALXN competitors.
CELG GILD REGN VRTX BIIB AGIO RARE IONS QGEN XON
  • ALXN Historical Net Revenue (Sales) Table
    in $ million
    Year Net Revenue (Sales) YoY % Change Stock Price YoY % Change (Stock Price)
    4/1/2021 $1,591 -72.8% - -
    4/1/2020 $5,862 23.8% - -
    4/1/2019 $4,735 21.0% - -
    4/1/2018 $3,912 12.7% - -
    4/1/2017 $3,471 61.1% - -
    4/1/2016 $2,155 -13.9% - -
    4/1/2015 $2,502 20.5% - -
    4/1/2014 $2,076 45.2% - -
    4/1/2013 $1,429 37.3% - -
    4/1/2012 $1,041 46.3% - -
    4/1/2011 $711 43.6% - -
    4/1/2010 $495 40.2% - -
    4/1/2009 $353 64.0% - -
    4/1/2008 $215 461.8% - -
    4/1/2007 $38 2337.8% - -
    4/1/2006 $1 6.4% - -
    4/1/2005 $1 -67.9% - -
    4/1/2004 $4 534.8% - -
    4/1/2003 $0 -85.5% - -
    4/1/2002 $4 -50.6% - -
    4/1/2001 $10 -45.1% - -
    4/1/2000 $18 -26.0% - -
    4/1/1999 $24 1506.5% - -
    4/1/1998 $1 -77.9% - -
    4/1/1997 $7 133.3% - -
    4/1/1996 $3 500.0% - -
    4/1/1995 $0 - - -

  • About
    Industry: Biotechnology
    Sector: Healthcare
    Country: US
    IPO Date: 2/1/1996
    Stonk Exchange: NASDAQ
    • Alexion Pharmaceuticals, Inc
    • is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.
    • The company is headquartered in Boston, Massachusetts and currently employs 2,656 full-time employees.
    • The firm is focused on the development and commercialization of therapeutic products.
    • The firm's products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa).
    • The firm's clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
    • Its Soliris is the therapeutic approved for patients with either paroxysmal nocturnal hemoglobinuria (PNH) or hemolytic uremic syndrome (aHUS).
    • PNH and aHUS result from chronic uncontrolled activation of the complement component of the immune system.
    • Its Strensiq is for the treatment of patients with Hypophosphatasia (HPP).
    • Its product, Kanuma is for the treatment of patients with Lysosomal Acid Lipase Deficiency (LAL-D).
    • The company is a recombinant form of the human LAL enzyme, which is a replacement therapy that is approved for the treatment for patients with LAL-D.

  • "The Top Line"

    The revenue (or sales) is the value of a company's sales of goods and services to its customers. Although a company's bottom line (its net income) gets most of the attention from investors, the top line is where the revenue or income process begins. Also, in the long run, profit margins on a company's existing products tend to eventually reach a maximum that is difficult to improve. Thus, companies typically can grow no faster than their revenues.

    For more detailed definitions, please see Investopedia.